An NCI-designated Comprehensive Cancer Center
First-ever platform trial for targeted treatments in multiple myeloma
September 24, 2019 | by City of Hope
Despite the availability of many emerging treatments for multiple myeloma, it remains an incurable cancer. As a pioneer in advancing personalized medicine and commitment to improved patient outcomes, City of Hope experts have joined efforts for a unique clinical trial.
Research Highlights
Stacy Gray, M.D. - Profile Photo
Stacy Gray, M.D. Receives NIH Grant for Cancer Genomics Research
September 11, 2019 | by Letisia Marquez
Stacy Gray, M.D., associate clinical professor in the Division of Clinical Cancer Genomics, is one of six physicians to receive an inaugural “Genomic Innovator Award” from the National Human Genome Institute (NHGI).
Research Highlights
breakthroughs - liver cancer
ET140202 Artemis T Cell therapy for the treatment of liver cancer
August 20, 2019 | by City of Hope
City of Hope is the first institution in the United States to open an immunotherapy clinical trial for liver cancer that eventually could transform treatment of the usually fatal disease into an outpatient procedure.
Clinical Trials | Treatments
HPV cells
Innovative approach using KITE-439 in targeting HPV-related malignancies
August 20, 2019 | by City of Hope
HPV16-induced cancers, a strain that causes about 70% of all cervical cancers worldwide, are ideal candidates for targeted T cell therapy due to their nonself antigens.
Treatments | Clinical Trials
Breakthroughs - prostate cancer clinical trial
PSCA as a novel CAR T target for resistant prostate cancer
August 20, 2019 | by City of Hope
In this phase 1 trial, the safety and tolerability of autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes are studied in adult patients with PSCA+ metastatic castration-resistant prostate cancer.
Clinical Trials
Natural Killer Cells | City of Hope
Anti-PD-L1 checkpoint inhibitors: Decoding the mystery
July 24, 2019 | by City of Hope
An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.
Research Highlights